Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai

You may also be interested in...



For BIO, All Roads Lead To India; World Class R&D Apt For Deals But Lack Of Data Protection Create Reticence

 

For BIO, All Roads Lead To India; World Class R&D Apt For Deals But Lack Of Data Protection Create Reticence

 

BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 2 of 2)

WASHINGTON - BIO President Jim Greenwood recently returned from a trip across India aimed at drumming up interest in the BIO India Partnering Conference in September 2010; he touted India's burgeoning innovative biotech industry and discussed the growing interest of BIO in seeking new or expanded partnerships with Indian firms.

Related Content

UsernamePublicRestriction

Register

SC070520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel